Claims for Patent: 11,389,461

Summary for Patent: 11,389,461

Title:	Spironolactone aqueous compositions
Abstract:	Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
Inventor(s):	Pipho; Anthony (Winterville, NC), DeHart; Michael Paul (Winterville, NC)
Assignee:	CMP DEVELOPMENT LLC (Farmville, NC)
Application Number:	17/383,770
Patent Claims:	1. A ready-to-use liquid formulation, comprising: micronized spironolactone in an amount of about 5 mg/mL; xanthan gum in an amount to provide a formulation viscosity of from 100 cP to 300 cP, glycerin in an amount of from 18 mg/mL to 24 mg/mL; a sufficient amount of a citrate buffer to maintain a pH of the formulation from 4.5 to 5.5 and a water vehicle. 2. The ready-to-use liquid formulation of claim 1, wherein the micronized spironolactone has a median volume particle size of not more than about 9.6 .mu.m. 3. The ready-to-use liquid formulation of claim 1, wherein the micronized spironolactone has a median volume particle size of about 3.6 .mu.m to about 9.6 .mu.m. 4. The ready-to-use liquid formulation of claim 1, wherein the xanthan gum is present in an amount of from 1.3 mg/mL to 3.6 mg/mL. 5. The ready-to-use liquid formulation of claim 1, wherein the xanthan gum is present in an amount of from 1.8 mg/mL to 3.6 mg/mL. 6. The ready-to-use liquid formulation of claim 1, wherein the glycerin is present in an amount of from 18 mg/mL to 22 mg/mL. 7. The ready-to-use liquid formulation of claim 1, wherein the citrate buffer is present in an amount of from about 10 mM to about 100 mM. 8. The ready-to-use liquid formulation of claim 1, wherein the citrate buffer is present in an amount of from about 10 mM to about 100 mM and wherein the pH of the formulation ranges from 4.8 to 5.2. 9. The ready-to-use liquid formulation of claim 1, wherein the citrate buffer comprises from 1.7 mg/mL to 2.4 mg/mL citric acid and from 3.6 mg/mL to 4.8 mg/mL sodium citrate. 10. The ready-to-use liquid formulation of claim 1, wherein the formulation viscosity ranges from 130 cP to 170 cP. 11. The ready-to-use liquid formulation of claim 1, wherein the spironolactone content is 100.+-.10% of labeled content when stored under 25.+-..degree. C. and 40% relative humidity for 12-months. 12. A ready-to-use liquid formulation, comprising: micronized spironolactone in an amount of about 5 mg/mL; xanthan gum in an amount to provide a formulation viscosity of from 100 cP to 300 cP, a dispersing agent consisting of glycerin in an amount of from 18 mg/mL to 24 mg/mL; a sufficient amount of a citrate buffer to maintain a pH of the formulation from 4.5 to 5.5 and a water vehicle. 13. The ready-to-use liquid formulation of claim 12, wherein the micronized spironolactone has a median volume particle size of not more than about 9.6 .mu.m. 14. The ready-to-use liquid formulation of claim 12, wherein the micronized spironolactone has a median volume particle size of about 3.6 .mu.m to about 9.6 .mu.m. 15. The ready-to-use liquid formulation of claim 12, wherein the xanthan gum is present in an amount of from 1.3 mg/mL to 3.6 mg/mL. 16. The ready-to-use liquid formulation of claim 12, wherein the xanthan gum is present in an amount of from 1.8 mg/mL to 3.6 mg/mL. 17. The ready-to-use liquid formulation of claim 12, wherein the glycerin is present in an amount of from 18 mg/mL to 22 mg/mL. 18. The ready-to-use liquid formulation of claim 12, wherein the citrate buffer is present in an amount of from about 10 mM to about 100 mM. 19. The ready-to-use liquid formulation of claim 12, wherein citrate buffer is present in an amount of from about 10 mM to about 100 mM and wherein the pH of the formulation ranges from 4.8 to 5.2. 20. The ready-to-use liquid formulation of claim 12, wherein the citrate buffer comprises from 1.7 mg/mL to 2.4 mg/mL citric acid and/or from 3.6 mg/mL to 4.8 mg/mL sodium citrate. 21. The ready-to-use liquid formulation of claim 12, wherein the formulation viscosity ranges from 130 cP to 170 cP. 22. The ready-to-use liquid formulation of claim 12, wherein the spironolactone content is 100.+-.10% of labeled content when stored under 25.+-..degree. C. and 40% relative humidity for 12-months. 23. The ready-to-use liquid formulation of claim 1, wherein the formulation viscosity ranges from 120 cP to 170 cP. 24. The ready-to-use liquid formulation of claim 1, wherein the formulation viscosity ranges from 150 cP to 170 cP. 25. The ready-to-use liquid formulation of claim 1, wherein the xanthan gum is from 1.3 mg/mL to 3.0 mg/mL. 26. The ready-to-use liquid formulation of claim 1, wherein the micronized spironolactone has a median volume particle size of about 3.6 .mu.m. 27. The ready-to-use liquid formulation of claim 12, wherein the formulation viscosity ranges from 120 cP to 170 cP. 28. The ready-to-use liquid formulation of claim 12, wherein the formulation viscosity ranges from 150 cP to 170 cP. 29. The ready-to-use liquid formulation of claim 12, wherein the xanthan gum is from 1.3 mg/mL to 3.0 mg/mL. 30. The ready-to-use liquid formulation of claim 12, wherein the micronized spironolactone has a median volume particle size of about 3.6 .mu.m.